Login to Your Account



Clinic Roundup


Thursday, June 9, 2011
• PharmaMar, a subsidiary of Zeltia SA, based in Madrid, began a Phase II trial of its pancreatic cancer candidate, PM001183. The trial will enroll between 21 and 43 adults with metastatic exocrine pancreatic cancer who have failed standard therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription